Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design
about
Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitorHIV-1 integrase inhibitor resistance and its clinical implicationsBroad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137)Integrase Inhibitor Prodrugs: Approaches to Enhancing the Anti-HIV Activity of β-Diketo AcidsNovel therapeutic strategies targeting HIV integraseCrystal structure of the HIV-1 integrase core domain in complex with sucrose reveals details of an allosteric inhibitory binding siteA historical sketch of the discovery and development of HIV-1 integrase inhibitorsUnprocessed viral DNA could be the primary target of the HIV-1 integrase inhibitor raltegravirAccessible high-throughput virtual screening molecular docking software for students and educatorsMolecular features related to HIV integrase inhibition obtained from structure- and ligand-based approachesMeasuring rapid hydrogen exchange in the homodimeric 36 kDa HIV-1 integrase catalytic core domainIn-Silico docking of HIV-1 integrase inhibitors reveals a novel drug type acting on an enzyme/DNA reaction intermediate.Development of pharmacophore similarity-based quantitative activity hypothesis and its applicability domain: applied on a diverse data-set of HIV-1 integrase inhibitors.An inhibitory monoclonal antibody binds at the turn of the helix-turn-helix motif in the N-terminal domain of HIV-1 integrase.Targeting Tn5 transposase identifies human immunodeficiency virus type 1 inhibitors.Identification of an inhibitor-binding site to HIV-1 integrase with affinity acetylation and mass spectrometry.Homogeneous high-throughput screening assays for HIV-1 integrase 3beta-processing and strand transfer activities.A novel small molecular weight compound with a carbazole structure that demonstrates potent human immunodeficiency virus type-1 integrase inhibitory activity.Revealing domain structure through linker-scanning analysis of the murine leukemia virus (MuLV) RNase H and MuLV and human immunodeficiency virus type 1 integrase proteinsAn unusual helix turn helix motif in the catalytic core of HIV-1 integrase binds viral DNA and LEDGF.A dynamic model of HIV integrase inhibition and drug resistance.Genetic analyses of DNA-binding mutants in the catalytic core domain of human immunodeficiency virus type 1 integrase.The HIV-1 integrase α4-helix involved in LTR-DNA recognition is also a highly antigenic peptide elementHIV-1 IN inhibitors: 2010 update and perspectivesBiochemical and pharmacological analyses of HIV-1 integrase flexible loop mutants resistant to raltegravirSolution conformation and dynamics of the HIV-1 integrase core domain.Effect of HIV integrase inhibitors on the RAG1/2 recombinase.Therapeutic strategies underpinning the development of novel techniques for the treatment of HIV infection.Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes.Structure-based HIV-1 integrase inhibitor design: a future perspective.Inhibition of human immunodeficiency virus type 1 integration by diketo derivativesEffect of raltegravir resistance mutations in HIV-1 integrase on viral fitnessHuman immunodeficiency virus type 1 (HIV-1) integrase: resistance to diketo acid integrase inhibitors impairs HIV-1 replication and integration and confers cross-resistance to L-chicoric acid.Molecular dynamics studies of the wild-type and double mutant HIV-1 integrase complexed with the 5CITEP inhibitor: mechanism for inhibition and drug resistanceBinding site in eag voltage sensor accommodates a variety of ions and is accessible in closed channel.HIV integrase, a brief overview from chemistry to therapeutics.Peptides that inhibit HIV-1 integrase by blocking its protein-protein interactions.Inhibitor design by wrapping packing defects in HIV-1 proteins.Basic quinolinonyl diketo acid derivatives as inhibitors of HIV integrase and their activity against RNase H function of reverse transcriptase.Discovery of a small-molecule HIV-1 integrase inhibitor-binding site
P2860
Q24611984-0637434B-3DA7-417C-9047-0626AE703235Q24628743-B995E9ED-EE11-4305-AEB6-06A400AB1B0AQ24656978-03599908-DE75-4F20-82C4-3F7AED11D8C9Q26800036-84E2C2FC-520C-44F1-9CAA-28D46E708A8EQ27003960-AC54A2E7-FD8E-4105-9919-4A4C7BF0BB0BQ27660224-392D6DEF-560B-4341-BED3-7E3EB26A1C9FQ28274166-C54ABE83-032B-4BE2-99E3-C95AE5D3A9F2Q28480958-C2C3AF8C-3727-4357-B291-FDFFA230E58AQ28484021-924D3D30-7327-4944-A592-A565E0669633Q28538414-602B5284-9C59-4175-BB23-6525C575EB64Q30398335-1A416A65-F7EF-4871-A3F1-40A92DE6CE34Q30479242-79E672C0-3715-40BD-BFBA-7ACF4D07535FQ30801514-36019D75-3360-4871-B188-619B76BE7E1BQ30915736-C72ECC5B-F2CE-4F99-862E-888FEFEA1BC5Q31164008-6BCA270D-FD82-465B-8C36-2A04AE1B9EDCQ33202469-611A80A8-3730-4A03-8850-175353BD60C2Q33221506-0912A158-E9F5-4ADA-85FC-4B5F4DAF78A9Q33228536-BC59BFF3-2F07-4C78-8CA2-A443EC25E38FQ33257614-134FE64B-D114-47AD-97BE-B96C457ECF90Q33396954-8CA9EB0B-DAB0-4590-9BDA-95ABFAC4ED1EQ33758191-47E5522C-91D2-4903-829B-853B2D9B5664Q33782016-89BDF75F-1D49-49AB-AD02-CB7ABF942AFDQ33786815-46831351-702A-4BCE-B5E3-E0BA72752A8FQ33814351-FDE5BD53-95B9-434F-BF58-4AE1F1ED7EB6Q33838063-3D3F4F29-3DB1-4115-9299-872E4A037A85Q33885382-BAF4C590-4535-4495-B8B5-45235ABC5E70Q33896796-7EC3A98F-6B6B-4A1D-BC2D-0903071A8676Q34021729-81A708DA-8F45-46B2-A09D-43C1E4B9C8A5Q34067223-F8A299BC-E49B-49A5-8ADB-1F2707D75815Q34141071-230667C8-070A-44CD-9251-98EF8A0DBD61Q34143182-7AC41D9F-8CE2-4831-BB49-E735FAE9A010Q34148077-4F3467D5-3399-4494-A33E-183BE1F03D10Q34151301-230DDBAD-1908-4FD8-BF8D-20AA8FBE32BAQ34180538-67D06BE2-78EB-492F-920A-9E2A22757CC5Q34187651-801CB53A-BA43-4C99-9088-2F683827C35EQ34247770-4DFA90D2-2AE7-4DBB-90BC-6587D398D909Q34320018-7A34A1F9-D15B-4BF4-A020-1B3339D6DF95Q34338157-B0C3FCC6-1D0B-4DBE-AD9F-C214F01F6B4FQ34372481-6D2BDBD2-9C14-404F-AA44-84B04A4D6496Q34772524-A0A3AB6A-498B-42D0-9A94-9468B9598E4A
P2860
Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design
description
1999 nî lūn-bûn
@nan
1999 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Structure of the HIV-1 integra ...... form for antiviral drug design
@ast
Structure of the HIV-1 integra ...... form for antiviral drug design
@en
Structure of the HIV-1 integra ...... form for antiviral drug design
@nl
type
label
Structure of the HIV-1 integra ...... form for antiviral drug design
@ast
Structure of the HIV-1 integra ...... form for antiviral drug design
@en
Structure of the HIV-1 integra ...... form for antiviral drug design
@nl
prefLabel
Structure of the HIV-1 integra ...... form for antiviral drug design
@ast
Structure of the HIV-1 integra ...... form for antiviral drug design
@en
Structure of the HIV-1 integra ...... form for antiviral drug design
@nl
P2093
P2860
P356
P1476
Structure of the HIV-1 integra ...... form for antiviral drug design
@en
P2093
D R Davies
H Sugimoto
T Fujishita
T Fujiwara
T Yoshinaga
P2860
P304
P356
10.1073/PNAS.96.23.13040
P407
P577
1999-11-09T00:00:00Z